Last checked at 2 Jul 2020 16:08
Â
Â
Â
Â
2 July 2020
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Â
Director/PDMR Shareholding
Â
The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 30 June and 1 July 2020 it purchased 100,000 and 60,000 Ordinary Shares of 1p, respectively, in the capital of the Company ("Ordinary Shares") at an average price of 3.95p per Ordinary Share (the "Purchase"). Following the Purchase, Vulpes has a total direct and indirect interest in 65,363,158 Ordinary Shares, equivalent to 22.14% of Proteome Sciences' total issued share capital.
Â
The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes Investment Management and the Company, he now has an interest in 65,363,158 Ordinary Shares of the Company representing 22.14% of the issued share capital of the Company.
Â
The below notification is made in accordance with the requirements of the EU Market Abuse regulation.
Â
1. | Details of the person discharging managerial responsibilities/person closely associated | |||||||
a) | Name: | Martin Diggle | ||||||
 | Reason for the notification | |||||||
a) | Position/status: | Non-Executive Director | ||||||
b) | Initial notification/Amendment: | Initial Notification | ||||||
 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name: | Proteome Sciences Plc | ||||||
b) | LEI: | 213800Q62ICXANKU2986 | ||||||
 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary Shares of 1p nominal value GB0003104196 | ||||||
b) | Nature of the transaction: | Purchase of Ordinary Shares | ||||||
c) | Price(s) and volume(s): | Â
 | ||||||
d) | Aggregated information: · Aggregated volume: · Price: | Single transaction as in 4 c) above
 | ||||||
e) | Date of the transaction: | 30 June and 1 July 2020 respectively | ||||||
f) | Place of the transaction: | London Stock Exchange, AIM (XLON) | ||||||
Â
For further information:
Â
Proteome Sciences plc | Â | |
Dr Ian Pike, Interim Chief Executive Officer/ Chief Scientific Officer  | Tel: +44 (0)20 7043 2116 |  |
Richard Dennis, Chief Commercial Officer | Â | Â |
 |  |  |
Allenby Capital Limited (Nominated Adviser & Broker) | Â | |
John Depasquale / Jeremy Porter  | Tel: +44 (0) 20 3328 5656 | |
Â
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.
Â